A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse." (I2D IFM2021_03)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04998786 |
Recruitment Status :
Active, not recruiting
First Posted : August 10, 2021
Last Update Posted : May 30, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
This is a phase II, multicenter, open-label study to evaluate the rate of patients achieving very good partial response (VGPR) or better to the oral combination Iberdomide Ixazomib Dexamethasone in elderly patients with multiple myeloma at first relapse .
The patient population will consist of adult men and women more than 70 years, who meet eligibility criteria.
Following the screening period, patients will be enrolled and treated then, they will receive therapy with Iberdomide, Ixazomib and Dexaméthasone during 6 cycles and Iberdomide and Ixazomib until progression.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Multiple Myeloma at First Relapse | Drug: Ixazomib Drug: Iberdomide Drug: Dexamethasone Oral | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 80 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse." |
Actual Study Start Date : | December 14, 2021 |
Estimated Primary Completion Date : | January 1, 2025 |
Estimated Study Completion Date : | January 1, 2027 |
Arm | Intervention/treatment |
---|---|
Experimental: assessment of treatment Ixazomib, dexamethasone, iberdomide
Iberdomide, Ixazomib and Dexaméthasone during 6 cycles and Iberdomide and Ixazomib until progression
|
Drug: Ixazomib
Ixazomib 3 mg/day (days 1, 8, 15) cycle 1 to until progress Drug: Iberdomide Iberdomide 1.6 mg / day (day 1 to 21) cycle 1 to until progress Drug: Dexamethasone Oral Cycle 1 and 2 Dexaméthasone 20 mg/day on days 1, 8, 15, 22 Cycle 3 to 6 Dexamethasone 10 mg/day on days 1, 8, 15, 22 |
- Percentage of patients have very good partial response (VGPR) or better [ Time Frame: approximate 18 months ]Using IMWG criteria
- Number of adverse events [ Time Frame: approximate 18 months ]Number of adverse events defined by Common Terminology Criteria for Adverse Events (v5)
- Number of responses [ Time Frame: 3 months ]Partial Response (PR), Very Good Partial Response (VGPR), Complete Response (CR) and minor response (MR) will be evaluated according to IMWG
- Number of responses [ Time Frame: 6 months ]Partial Response (PR), Very Good Partial Response (VGPR), Complete Response (CR) and minor response (MR) will be evaluated according to IMWG
- Number of the death [ Time Frame: approximate 18 months ]is defined as the time in months from inclusion to the date of death due to any cause. Subject alive will be censored at the last known alive date.
- Number of progression [ Time Frame: approximate 18 months ]is defined as the time in months from inclusion to the date of disease progression or death due to any cause, using IMWG criteria
- Percentage of time to progression [ Time Frame: approximative 18 months ]is defined as the time in months from inclusion to the date of disease progression or death due to any cause, using IMWG criteria
- Percentage of duration of response [ Time Frame: approximative 18 months ]is defined as the time from the first response (PR or better) to the date of disease progression or death due to any cause
- Percentage of duration of therapy [ Time Frame: approximative 18 months ]is defined as the time from treatment initiation to the last dose of therapy
- Percentage of time to response [ Time Frame: approximative 18 months ]according IMWG
- Percentage of Overall Response Rate [ Time Frame: approximative 18 months ]according IMWG
- Percentage of value of biological prognostic factors [ Time Frame: day 1 ]prognostic factors as ISS stage, cytogenetic as del(17p), t(4;14),
- Percentage of frailty scores [ Time Frame: day 1 ]age, ECOG, comorbidity index
- Percentage of score of quality of life [ Time Frame: approximative 18 months ]To assess Quality of Life EQ5D and SF36
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 70 Years and older (Older Adult) |
Sexes Eligible for Study: | All |
Gender Based Eligibility: | Yes |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age > 70 years
- Eastern Collaborative Oncology Group (ECOG) performance score of ≤2
- Life expectancy > 6 months
- Voluntary written informed consent must be given before performance of any study-related procedure not part of normal medical care, with the understanding that the subject may withdraw consent at any time without prejudice to future medical care.
-
Symptomatic multiple myeloma (MM) at first relapse, as defined below:
- Symptomatic multiple myeloma according to international criteria.(Rajkumar et al, 2014)
- Relapsed MM is defined as previously treated MM that progresses and requires initiation of salvage therapy.
- Subject must have received one prior line of therapy for at least 3 cycles.
-
Subject has measurable disease at Screening, defined at least one of the following:
- Serum M-protein ≥ 0.5 gram (g)/deciliter (dL), OR
- Urine M-protein ≥ 200 mg in 24 hours, OR
- Serum immunoglobulin free light chain (FLC) ≥ 10 mg/dL provided serum FLC ratio is abnormal.
-
Subjects must meet the following laboratory parameters, per laboratory reference range (performed at most 15 days before cycle 1 day 1):
- Absolute neutrophil count (ANC) ≥ 1000/microliter (μL). Subjects may use growth factor support to achieve ANC eligibility criteria.
-
Platelet count ≥ 75,000 /mm3 for subjects in whom < 50% of bone marrow nucleated cells are plasma cells; or a platelet count ≥ 50,000/mm3 for subjects in whom > 50% of bone marrow nucleated cells are plasma cells. It is not permissible to transfuse subjects to achieve minimum platelet counts within 3 days before study.
--AST and ALT ≤ 3 × upper limit of normal (ULN).
- Total bilirubin ≤ 1.5 × ULN. Subjects with documented Gilbert's syndrome may have bilirubin > 1.5 × ULN with the approval of the Primary Therapeutic Area Medical Director
- Creatinine clearance (CrCl) ≥ 30 milliliter (mL)/minute (min) (using Cockroft and Gault Formula)
- Patient should comply with Celgene's pregnancy prevention plan for Iberdomide (please see appendix 8 Iberdomide Pregnancy Prevention Plan for subjects in clinical trials)
-
Female patients who:
- are postmenopausal for at least 24 months before the screnning visit, OR
- are surgically sterile (have undergone a hysterectomy or bilateral oophorectomy)
- Men even if surgically sterilized must agree to not father a child and agree to practice complete abstinence or to use a condom during therapy and dose interruptions and for 90 days after the last dose of study drug, even if they have had a successful vasectomy, if their partner is of childbearing potential or pregnant.
Non-inclusion Criteria:
- Subject is refractory to bortezomib, defined as progression on or within 60 days of the last dose of bortezomib.
- Subject has had prior treatment with ixazomib, carfilzomib, pomalidomide or iberdomide
-
Subject has any of the following conditions:
- Non-secretory or oligo-secretory MM
- Light chain Amyloidosis (AL Amyloidosis)
- POEMS syndrome Waldenström macroglobulinemia
- Known Human Immunodeficiency Viral (HIV) infection
- Active hepatitis B or C infection based on blood screen tests
- Significant cardiovascular or pericardial disease, including uncontrolled angina, hypertension, arrhythmia, recent myocardial infarction within 6 months, congestive, heart failure New York Heart Association (NYHA) Class ≥ 3
- Major surgery within 4 weeks prior screening
- Acute infections requiring parenteral therapy (antibiotic, antifungal or antiviral) within 14 days
- ≥ Grade 3 Peripheral neuropathy or grade 2 with pain
- Uncontrolled diabetes or uncontrolled hypertension within 14 days
- Any other medical condition that, in the opinion of the Investigator, would adversely affect the subject's participation in the study
-
Subject has a history of other active malignancies, including myelodysplastic syndrome (MDS), within the past 3 years prior to study entry, with the following exceptions:
- Adequately treated in situ carcinoma of the cervix uteri or the breast,
- Basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin,
- Prostate cancer Gleason grade 6 or lower AND with stable Prostate Specific Antigen (PSA) levels off treatment,
- Previous malignancy with no evidence of disease confined and surgically resected (or treated with other modalities) with curative intent and unlikely to impact survival during the duration of the study.
- Known intolerance to steroid therapy
- Serious medical or psychiatric illness likely to interfere with participation in study
- Incidence of gastrointestinal disease that may significantly alter the absorption of oral drugs
- Subjects unable or unwilling to undergo antithrombotic prophylactic treatment
- Person under guardianship, trusteeship or deprived of freedom by a judicial or administrative decision
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04998786
Principal Investigator: | Cyrille Touzeau | Nantes University Hospital |
Responsible Party: | Nantes University Hospital |
ClinicalTrials.gov Identifier: | NCT04998786 |
Other Study ID Numbers: |
RC21_0169 2021-001587-13 ( EudraCT Number ) |
First Posted: | August 10, 2021 Key Record Dates |
Last Update Posted: | May 30, 2023 |
Last Verified: | May 2023 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Multiple Myeloma, elderly patients, first relapse, previous exposed, High Risk, Ixazomib, Iberdomide, Dexametasone |
Multiple Myeloma Neoplasms, Plasma Cell Recurrence Neoplasms by Histologic Type Neoplasms Hemostatic Disorders Vascular Diseases Cardiovascular Diseases Paraproteinemias Blood Protein Disorders Hematologic Diseases Hemorrhagic Disorders Lymphoproliferative Disorders Immunoproliferative Disorders Immune System Diseases |
Disease Attributes Pathologic Processes Dexamethasone Ixazomib Anti-Inflammatory Agents Antiemetics Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Gastrointestinal Agents Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Antineoplastic Agents, Hormonal Antineoplastic Agents |